No ratings currently available, see text in Ratings section
below for explanation.
UR Medicine Faculty
The University of Rochester Medical Faculty Group
(URMFG) consists of over 900 specialist and primary care providers spanning 19
departments.
URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner
Accountable Health Partners (AHP) is a network of
over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the
region. AHP offers a full range of care.
My passion is direct patient care that is comprehensive in treating the "whole patient" and family-centered by including children and their families in the development of the care plan. As a pediatric hospitalist, I provide care to hospitalized pediatric patients of all ages from infancy thru adole...
My passion is direct patient care that is comprehensive in treating the "whole patient" and family-centered by including children and their families in the development of the care plan. As a pediatric hospitalist, I provide care to hospitalized pediatric patients of all ages from infancy thru adolescence that are acutely ill or have medically complex conditions. This includes providing pediatric consultation to subspecialty and surgical patients and coordination of care among multiple provider teams.
Education of patients and their families as well as medical students, residents, and colleagues is a fundamental part of my patient care activities. I also have a specific interest in development of individualized care plans for patients with complex medical care needs.
Certified Specialties
Pediatrics
- American Board of Pediatrics
Faculty Appointments
Professor (Part-Time)
-
Department of Pediatrics, Pediatric Hospitalist (SMD)
Credentials
Residency & Fellowship
Fellowship, Pediatrics, University of Rochester Medical Center. 1984 - 1987
Residency, Pediatrics, University of Massachusetts Medical Center. 1982 - 1984
Internship, Pediatrics, University of Massachusetts Medical Center. 1981 - 1982
Education
MD | University of Rochester School of Medicine/Dentistry (USA).1981
Awards
Best Doctors in America.2004 - 2014
Alpha Omega Alpha (AOA) Medical Honor Society.2003 - 2010
George Washington Goler Associate Professor of Pediatrics.2002 - 2005
Jacob Gitelman Award.2002
Society of Pediatric Research.1998
Research Fellow, Leukemia Society of America.1987 - 1990
Wilmot Cancer Research Fellow.1987 - 1990
Bradford Fellow.1985 - 1986
Rochester Academy of Medicine OB-GYN Annual Award.1980
Paul Gyorgy Annual Award, La Leche League International.1980
Honor Society of Phi Beta Kappa.1977
Honor Society of the Order of the Cross and Crown.1977
Research
Dr. Asselin's research expertise is in clinical trials and clinical research to improve the care of patients with pediatric cancers. She serves as study investigator for two major international cooperative research groups, the Children's Oncology Group and the Dana-Farber Leukemia Consortium....
Dr. Asselin's research expertise is in clinical trials and clinical research to improve the care of patients with pediatric cancers. She serves as study investigator for two major international cooperative research groups, the Children's Oncology Group and the Dana-Farber Leukemia Consortium.
Through these groups she is actively involved in design and development of a number of studies of the treatment and biology of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Her specific areas of expertise are L-asparaginase pharmacology and immunology in treatment of ALL, treatment of T-cell disease (ALL and NHL), and the role of cardioprotection in prevention of cardiotoxocity in long-term survivors.
Lipshultz ER, Chow EJ, Doody DR, Armenian SH, Asselin BL, Baker KS, Bhatia S, Constine LS, Freyer DR, Kopp LM, Schwartz CL, Lipshultz SE, Vrooman LM
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.. 2022 March 131 (3):536-542. Epub 1900 01 01.
Ladas EJ, Orjuela M, Stevenson K, Cole PD, Lin M, Athale UH, Clavell LA, Leclerc JM, Michon B, Schorin MA, Welch JG, Asselin BL, Sallan SE, Silverman LB, Kelly KM
Nutrition.. 2016 October 32 (10):1103-1109.e1. Epub 03/28/2016.
Matloub Y, Stork L, Asselin B, Hunger SP, Borowitz M, Jones T, Bostrom B, Gastier-Foster JM, Heerema NA, Carroll A, Winick N, Carroll WL, Camitta B, Devidas M, Gaynon PS
Pediatric blood & cancer.. 2016 February 63 (2):255-61. Epub 10/20/2015.
Tower RL, Jones TL, Camitta BM, Asselin BL, Bell BA, Chauvenet A, Devidas M, Halperin EC, Pullen J, Shuster JJ, Winick N, Kurtzberg J
Journal of pediatric hematology/oncology.. 2014 July 36 (5):353-61. Epub 1900 01 01.
Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: A report from the Children's Oncology Group.
Tower RL, Jones TL, Camitta BM, Asselin BL, Bell BA, Chauvenet A, Devidas M, Halperin EC, Pullen J, Shuster JJ, Winick N, and Kurtzberg J.
Journal of Pediatric Hematology/Oncology. 2014; 36(5): 353-61.
Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Post-induction dexamethasone and individualized dosing of E. coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: Results from a randomized study, Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
Vrooman LM, Stevenson KE, Supko JG, O'Brien J, Dahlberg SE, Asselin BL, Athale UH, Clavell LA, Kelly KM, Kutok JL, Laverdiere C, Lipshultz SE, Michon B, Schorin M, Relling MV, Cohen HJ, Neuberg DS, Sallan SE, and Silverman LB.
Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: Associations with long-term echocardiographic outcomes.
Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, Colan SD, Neuberg DS, Dahlberg SE, Henkel JM, Asselin BL, Athale UH, Clavell LA, Laverdiere C, Michon B, Schorin MA, and Sallan SE.
Vrooman LM, Neuberg DS, Stevenson KE, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Larsen EC, Laverdière C, Michon B, Schorin M, Schwartz CL, Cohen HJ, Lipshultz SE, Silverman LB, Sallan SE
European journal of cancer : official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR).. 2011 June 47 (9):1373-9. Epub 04/20/2011.
Effectiveness of High Dose Methotrexate in T-cell Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Lymphoma: A Randomized Study by the Children's Oncology Group (POG 9404)
L-Asparaginase for Treatment of Childhood Acute Lymphoblastic Leukemia: What Have We Learned?
Asselin, BL.
Pediatric Blood Cancer. 2011; 57(3): 357-358.
Late Cardiac Status in Long-Term Survivors of Childhood High-Risk Acute Lymphoblastic Leukemia 8 Years After Continuous or Bolus Infusion of Doxorubicin: The Dana-Farber Cancer Institute ALL 91-01 Randomized Trial
Lipshultz, SE; Miller, TL; Lipsitz, SR; Neuberg, DS; Dahlberg, SE; Colan, SD; Silverman, LB; Henkel, JM; Cushman, LL; Asselin, BL; Clavell, LA; Athale, U; Michon, B; Laverdiere, C; Schorin, MA; Larsen, E; Usmani, N; Sallan, SE, for the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium.
J Clin Oncol. 2011; .
Polyethylene glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: A Children's Oncology Group Study (POG 8866)
Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; and Camitta BM.
Journal of Pediatric Hematology Oncology. 2011; 33(8): 610-16.
The low incidence of secondary acute myelogenous leukemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukemia: A report from the Dana-Farber Cancer Institute ALL Consortium
Vrooman LM, Neuberg DS, Stevenson KE, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Larsen EC, Laverdiere C, Michon B, Schorin M, Schwartz CL, Cohen HJ, Lipshultz SE, Silverman LB, and Sallan SE.
Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD
The Lancet. Oncology.. 2010 October 11 (10):950-61. Epub 09/16/2010.
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukemia: long-term follow-up of a prospective, randomized, multicentre trial.
Barry EV, Vrooman LM, Dahlberg SE, Neuberg DS, Asselin BL, Athale UH, Clavell LA, Larsen EC, Moghrabi A, Samson Y, Schorin MA, Cohen HJ, Lipshultz SE, Sallan SE, Silverman LB
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2008 March 126 (7):1106-11. Epub 1900 01 01.
Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.
Barry EV, Vrooman LM, Dahlberg SE, Neuberg DS, Asselin BL, Athale UH, Clavell LA, Larsen EC, Moghrabi A, Sanson Y, Schorin MA, Cohen HJ, Lipshultz SE, Sallan SE, and Silverman LB.
Barry E, DeAngelo DJ, Neuberg D, Stevenson K, Loh ML, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin M, Cohen HJ, Sallan SE, Silverman LB
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2007 March 125 (7):813-9. Epub 1900 01 01.
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.
Moghrabi A, Levy DE, Asselin BL, Barr R, Clavell L, Hurwitz C, Samson Y, Schorin M, Dalton VK, Lipshultz SE, Neuberg DS, Gelberg RD, Cohen HJ.
Blood First Edition Paper, prepublished online Sept 26, 2006. DOI 10.1182/blood-206-06-027714. 2007; 109(3): 896-904.
Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Salzer WL, Devias M, Shuster JJ, Wang C, Chauvenet A, Asselin BL, Camitta BM and Kurtzberg J.
J Pediatr Hematol/Oncol. 2007; 29(6): 369-375.
Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Favorable Outcome for Adolescents with Acute Lymphoblastic Leukemia (ALL) Treated on Dana-Farber Cancer Institute (DFCI; Boston, MA) ALL Consortium Protocols.
Barry EV, Deangelo DJ, Neuberg DS, Loh MS, Asselin BL, Barr R, Clavell L, Hurwitz C, Moghrabi A, Samson Y, Schorin M, Cohen HJ, Sallan SE and Silverman LB.
Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25(7): 813-9.
Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Winter SS, Jiang Z, Khawaja H, Griffin T, Devidas M, Asselin BL, and Larsen RS.
Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE
The New England journal of medicine.. 2004 July 8351 (2):145-53. Epub 1900 01 01.
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
Lipshultz SE, Nader R, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr, RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD and Sallan SE.
Dalton VK, Rue M, Silverman LB, Gelber RD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin M, Tarbell NJ, Sallan SE, Cohen LE
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2003 August 121 (15):2953-60. Epub 1900 01 01.
Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment.
Dalton VK, Rue M, Silverman LB, Gelber RD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samaon Y, Schorin M, Tarbell NJ, Sallan SE, and Cohen LE.
J Clin Oncol. 2003; 21(15): 2953-60.
Childhood T-Cell Acute Lymphoblastic Leukemia (ALL): the Dana-Farber Cancer Institute ALL Consortium experience.
Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, Cohen HJ, Sallan SE and Asselin BL.
Doxorubicin administration by continuous infusion is not cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol
Lipshultz SE, Giantris AL, Lipsitz SR, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE, and Colan SD.
Graham ML, Asselin BL, Herndon JE, Casey JR, Chaffee S, Ciocci GH, Daeschner CW, Davis AR, Gold S, Halperin EC, Laughlin MJ, Martin PL, Olson JF, Kurtzberg J
Bone marrow transplantation.. 1998 May 21 (9):879-85. Epub 1900 01 01.
Anthracycline Induced Cardiotoxicity
Giantris A, Abdurrahman L, Hinkle A, Asselin BL, Lipshultz S.
Critical Reviews in Oncology-Hematology. 1998; 27: 53-68.
Toxicity, pharmacology and feasibility of administration of PEG-L-Asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia.
Graham ML, Asselin, BL, Herndon JE, III, Casey JR, Chaffee S. Ciocci GH, Daeschner CW, Davis AR, Gold S, Halperin EC, Laughlin MJ, Martin PL, Olson JF, and Kurtzberg J.
Chapter: "Treatment for Childhood Acute Lymphoblastic Leukemia: The Dana-Farber Cancer Institute Consortium Experience"
Authors: Silverman LB, Asselin BL, Sallan SE
Publisher:
Baylor-Sammons Cancer Center, Dallas, TX 1997
Conn's Current Therapy
(1994)
Chapter: "Nonimmune Hemolytic Anemia"
Authors: Asselin BL, Segel GB.
Publisher:
W.B. Saunders Co. 1994
Primary Pediatric Care
(1992)
Chapter: "The Leukemias of Childhood"
Authors: Asselin BL
Publisher:
C.V. Mosby Co., St. Louis, MO 1992
Ratings & Comments
At URMC, we believe that patients should be empowered to make the right decisions regarding their
personal
healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all
aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying
star ratings for our providers along with anonymous patient comments on our website. This will help you make
better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used
to generate this vital information. Learn more about
our survey process.
